These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38845409)

  • 1. Trends in the administration of COVID-19 vaccines with other vaccines in the United States reported to V-safe during December 14, 2020-May 19, 2023.
    Parker CE; Hause AM; Marquez P; Zhang B; Myers TR; Shay DK
    Hum Vaccin Immunother; 2024 Dec; 20(1):2361946. PubMed ID: 38845409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021.
    Hause AM; Baggs J; Gee J; Marquez P; Myers TR; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(39):1379-1384. PubMed ID: 34591835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
    Moro PL; Ennulat C; Brown H; Woody G; Zhang B; Marquez P; Woo EJ; Su JR
    Drug Saf; 2024 May; 47(5):487-493. PubMed ID: 38411838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
    Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference.
    Choi MJ; Yu YJ; Kim JW; Ju HJ; Shin SY; Yang YJ; Cheong HJ; Kim WJ; Kim C; Kim HJ; Yoon SK; Park SJ; Gwak W; Lee JW; Kim B; Song JY
    Clin Microbiol Infect; 2024 May; 30(5):653-659. PubMed ID: 38253313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
    Shay DK; Gee J; Su JR; Myers TR; Marquez P; Liu R; Zhang B; Licata C; Clark TA; Shimabukuro TT
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):680-684. PubMed ID: 33956784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses.
    Pattinson D; Jester P; Gu C; Guan L; Armbrust T; Petrie JG; King JP; Nguyen HQ; Belongia EA; Halfmann P; Neumann G; Kawaoka Y
    EBioMedicine; 2024 May; 103():105103. PubMed ID: 38574407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza Vaccinations During the COVID-19 Pandemic - 11 U.S. Jurisdictions, September-December 2020.
    Roman PC; Kirtland K; Zell ER; Jones-Jack N; Shaw L; Shrader L; Sprague C; Schultz J; Le Q; Nalla A; Kuramoto S; Cheng I; Woinarowicz M; Robison S; Robinson S; Meder K; Murphy A; Gibbs-Scharf L; Harris L; Murthy BP
    MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(45):1575-1578. PubMed ID: 34758010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
    Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
    Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US.
    Hause AM; Zhang B; Yue X; Marquez P; Myers TR; Parker C; Gee J; Su J; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2022 Jul; 5(7):e2222241. PubMed ID: 35838667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines.
    Kenigsberg TA; Goddard K; Hanson KE; Lewis N; Klein N; Irving SA; Naleway AL; Crane B; Kauffman TL; Xu S; Daley MF; Hurley LP; Kaiser R; Jackson LA; Jazwa A; Weintraub ES
    Vaccine; 2023 Sep; 41(39):5678-5682. PubMed ID: 37599140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study.
    Chen C; Chen C; Cao L; Fang J; Xiao J
    Int Immunopharmacol; 2024 May; 133():112022. PubMed ID: 38615382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.